Amgen Wins Delay Of Sandoz Biosimilar At Fed. Circ.
The Federal Circuit on Tuesday temporarily blocked Sandoz Inc. from selling a copycat version of Amgen Inc.'s blockbuster Neupogen, saying the product can't be sold until the court resolves a dispute...To view the full article, register now.
Already a subscriber? Click here to view full article